Skip to main content
. 2019 Sep 30;6(1):17–29. doi: 10.1002/cjp2.134

Figure 2.

Figure 2

Immunohistochemistry in malignant gliomas with monoclonal and polyclonal anti‐SEL1L antibodies. (A) Anaplastic astrocytoma, SEL1LA+ neurons, microglia/macrophages and mostly tumour cells; DAB, original magnification (OM) × 200. (B) Anaplastic astrocytoma, SEL1L‐p70/80+ neurons, microglia/macrophages and mostly tumour cells; DAB, OM × 200. (C) Anaplastic oligodendroglioma, SEL1LA+ tumour cells in the cytoplasm and nucleus; DAB, OM × 200. (D) Anaplastic oligodendroglioma, SEL1L‐p70/80+ tumour cells in the nucleus; DAB, OM × 200. (E) Anaplastic oligodendroglioma, SEL1LA+ tumour cells; DAB, OM × 200. (F) Anaplastic oligodendroglioma, Ki‐67/MIB‐1+ cells; DAB, OM × 200. (G) GB, H&E; DAB, OM × 400. (H) GB, SEL1LA+ tumour cells in the cytoplasm and nuclei; DAB, OM × 400; (I) GB, SEL1L‐p70/80+ tumour cells in the nucleus; DAB, OM × 400. (J) GB, SEL1L‐p70/80+ tumour and myeloid cells around a perinecrotic pseudopalisade; DAB, OM × 200. (K) GB, Nestin+ tumour cells; DAB, OM × 400. (L) GB, Sox2+ tumour cells; DAB, OM × 400. (M) GB, Ki‐67/MIB‐1+ cells; DAB, OM × 400. DAB, 3,3′‐diaminobenzidine.